The main route of metabolism of methotrexate (MTX) is known to be oxidation catalysed by hepatic aldehyde oxidase to 7-hydroxy MTX (7-0H MTX)/ however, a deglutamated metabolite deoxyaminopteroic acid (DAMPA) has also been detected in biological fluids of subjects receiving high dose MTX therapy.?
The main route of metabolism of methotrexate (MTX) is known to be oxidation catalysed by hepatic aldehyde oxidase to 7-hydroxy MTX (7-0H MTX)/ however, a deglutamated metabolite deoxyaminopteroic acid (DAMPA) has also been detected in biological fluids of subjects receiving high dose MTX therapy.?
The route of DAMPA formation has not yet been elucidated. It has been suggested that deglutamation results from gastro-intestinal bacterial metabolism.v 4 However, Donehower et al. 4 and Chatterji et al.S have claimed that DAMPA is an impurity in MTX infusions. A further metabolic product of MTX has been reported'' which was thought to be 7-hydroxy DAMPA (7-0H DAMPA). 7-0H DAMPA Correspondence: Dr M J Stewart. may be formed either by the deglutamation of 7-0H MTX" or by the oxidation of DAMPA (Fig. 1 ). In addition, polyglutamate metabolites may be formed intracellularly. 7 If 7-0H DAMPA is formed by the deglutamation of 7-0H MTX then 7-0H DAMPA should be found in patients receiving high dose MTX when 7-0H MTX is present in the plasma; however, if the route were by oxidation of DAMPA then 7-0H DAMPA would be found only in patients in whom DAMPA was present. Therefore, we undertook an in vivo study of MTX metabolites in serum and urine samples from patients exposed to high dose MTX using an HPLC method developed for the purpose, and in vitro studies of the oxidation of DAMPA using a liver homogenate previously described for the conversion of MTX to 7-0H MTX,K and the deglutamation of 7-0H MTX using cultures of bacteria commonly found in the GI tract.
Materials and methods

STANDARDS
MTX and DAMPA were donated by Lederle Ltd (American Cyanamid Company). 7-0H MTX reference standard was donated by Dr David G Johns (National Cancer Institute, Bethesda, Md, USA).
The di-and triglutamates of MTX were kindly provided by Professor C Baugh (University of Alabama, USA).
MATERIALS
Sephadex Gloo was obtained from Pharrnacia, Uppsala , Sweden; DEAE Cellulose was obtained from Whatman Biochemicals Ltd, Springfield Mill, Kent, UK. All other reagents were obtained from BDH Ltd, Poole, Dorset, UK.
PATIENTS' SPECIMENS
Plasma and urine samples were collected at intervals from patients during a period of 72 h following treatment with intravenous high-dose MTX for a variety of malignant conditions. Patients had all received leucovorin rescue over the 24 h following cessation of the MTX infusion. The volumes of urine samples were measured and both plasma and urine specimens stored at -20°C until analysed.
HPI.C CONDITIONS
The column used was 10 em x 5 mm id slurry packed with 5 I.l Hypersil ODS.
The mobile phase was methanol: 50 mM phosphoric acid containing O· I % hexanesulphonic acid (28:72); flow rate, 1 mUmin, with detection at 307 nm. Further details of the assay are given in Farid et al:"
A homogenate of rabbit liver was prepared as described elsewhere. II) Sodium sulphate was added to the crude fraction at 4°C to give a final concentration of 35% »dv . The crude fraction was centrifuged for 1 h. The precipitated protein was collected and the precipitate was redissolved in 40 mM Tris/HCI buffer; the solution was applied to a column of Sephadex Gloo and eluted with Tris/HCl buffer. The enzyme activity of the eluted fractions was assayed by incubation with MTX and analysis of the deproteinised reaction mixture by HPLC. A fraction containing 10 times the activity of the crude homogenate was collected.
To 6 mL of this enzyme fraction was added 4 ml of an aqueous solution containing 2 mg DAMPA. This mixture was incubated at 37°C and the progress of the reaction monitored using HPLC. K The reaction was stopped by boiling the mixture and centrifuging for 10 min at 2000 rpm. Although complete conversion of DAMPA can be achieved, 80% conversion was preferred as this allowed the remaining DAMPA to act as a marker and allow relative measurements on fractions collected as described below. The denatured incubation mixture was applied, after cooling, to a DEAE cellulose column (25 x 1 em id) and washed with 50 mL water. The column was then connected to a UVICORD detector set at 280 nm and the metabolites eluted at room temperature with 0·6 Mammonium bicarbonate. Fractions containing UV absorbing material at 280 nm were collected, the peak fractions pooled and freeze-dried repeatedly to remove ammonium bicarbonate. Samples were then scanned on a Beckman DU-7 HS spectrophotometer before more detailed analysis by HPLC, nuclear magnetic resonance spectroscopy and mass spectrometry.
BACTERICAL STUDIES
Strains of Citrobacter freundii, klebsiella pneumoniae, pseudomonas aeruginosa, Acinetobacter calcoaceius and Escherichia coli isolated from the GI tracts of patients in this hospital were incubated at 37°C in Mueller-Hinton broth in the presence of MTX at concentrations of 10-4_10-6 M. After 24 h, the cells were sedimented by centrifugation at 1500 g and the supernatant broth was stored at -20°C prior to assay. The bacterial pellets were washed twice with normal saline and also stored at -20°C. Broth and cells, ruptured by ultrasonication in distilled water, were subsequently analysed by HPLC.
MASS SPECTRAL AND NMR ANALYSES
High resolution mass spectra were obtained with an AEI MS9 instrument. NMR spectra of methotrexate in deuteromethanol (reference standard, TMS) and DAMPA and its metabolite in deuterium oxide containing NaOD (reference standard, tertiary butanol, 1·23) were recorded on a Bruker WM 250 spectrometer. 7-0H MTX was present in all plasma and urine samples. DAMPA was present in both plasma and urine in three patients. However, in one patient it was detected in only one course of treatment and in a further two patients it was detected during only two courses.
A third metabolite was detected in urine only when DAMPA was also present; it was not found in plasma.
A comparison of the plasma concentrationl time curves for MTX, DAMPA and 7-0H MTX in Fig. 2 shows that MTX and DAMPA show similar rapid falls following the end of the infusion whereas 7-0H MTX shows the initial rise and subsequent fall characteristic of a metabolite. The concentration of the third metabolite in each urine sample was approximately 10% of the corresponding DAMPA concentration, the cumulative excretion of MTX and its three metabolites in urine are shown in Fig. 3 for a patient in whom DAMPA and the metabolite were found in only one course of treatment. Since we postulated that the third metabolite was 7-0H DAMPA we attempted to obtain sufficient of this compound from the available urine specimen for characterisation by mass spectrum or NMR. This did not prove possible; however, we were left with a compound which gave a reproducible retention on HPLC with reference to MTX, 7-0H DAMPA and DAMPA. Accordingly we set about the syn-thesis of 7-0H DAMPA by the two postulated routes, in vitro.
TN VITRO STUDIES
In vitro preparation of oxidised metabolite of DAMPA Control samples of aldehyde oxidase fraction derived from rabbit liver, incubated without DAMPA at 37°for up to 6 h, and injected on to the HPLC column after deproteinisation, gave no peaks of elution volume greater than 1 mL when monitored at 307 nm.
The chromatograms obtained by sampling a reaction mixture containing DAMPA during an incubation are shown in Fig. 4 , where it can be seen that 100% conversion of DAMPA to a metabolite with an identical retention time to that of the in vivo metabolite was achieved. 50·0553 (54'8%) CHHHNO~150·0559 (13·6%) CHHHNOC haracterisation of reaction product Only two of the fractions obtained from the DEAE column showed significant absorption in the region of 307 nm, One (fraction 20) gave a UV spectrum identical to that of standard DAMPA, while the other (fraction 35) showed a modified spectrum (Fig. 5 ).
NMR and MS analysis
Although methotrexate does not give a satisfactory mass spectrum it was possible to obtain high-resolution mass spectra for DAMPA and the reaction product (Table 1) .
A molecular ion (M+) was observed in the mass spectrum of D AMPA; rn/z 325 (14 % ) with fragment ions at rn/z 176 and 151. The ion at rn/z 176 is ascribed to the 2,4-diamino-6pteridinyl fragment, which results from cleavage of the C 9_N 10 bond with hydrogen radical transfer. Similar fragmentation pathways were observed for the metabolite of DAMPA, with an M+ ion at mlz 341 and fragment ions at 192 and 151. The M+ ion had a mass 16 amu greater than the M+ of DAMPA, which is indicative of the introduction of oxygen into the molecule, possibly a hydroxyl group. The fact that there was an ion at rn/z 192 would indicate that the 2,4 diamino 6-pteridinyl group had been hydroxylated.
Comparison of the NMR spectra of DAMPA and its metabolite confirms that the 7-position has been hydroxylated ( Fig. 6 ), since the signal at 8·44 ascribed to the hydrogen at the 7position is not present in the spectrum of the metabolite. The metabolite was thus positively identified as 7-0H DAMPA.
BACTERIOLOGICAL STUDIES HPLC analyses of the supernatant broths from in vitro incubation of MTX and 7-0H MTX with gastro-intestinal bacteria revealed no peaks other than of the substrates added. Analysis of the bacterial pellets, however, revealed a peak which co-eluted an HPLC with authentic MTX triglutamate.
Discussion
The fact that DAMPA is not invariably present in the plasma of patients treated with high dose MTX again raises the question of its origin. Donehower et al," based their proposition that it is a product of metabolism by gut on the fact that total urinary excretion of DAMPA exceeded that detected in the infusion sachets. The possible role of bacteria has not been resolved by our studies using common strains of gastro-intestinal bacteria, since these had not been obtained from patients who had received high dose MTX and therefore the possibility of bacterial enzyme induction cannot be ruled out. The only metabolic product found was MTX triglutamate, based on HPLC evidence. Y We were unable to find DAMPA in 12 batches of MTX infusion fluid which we have analysed subsequent to our findings in patients. None of the batches used for treatment of the patients described was available for retrospective analysis. We were not in a position therefore to compare total DAMPA excretion with the amount present in the sachets. However, the kinetics of DAMPA as determined by the measurement of plasma concentrations, strongly suggest that the source of this metabolite was the infusion fluid, since DAMPA levels fall rapidly following cessation of the infusion, in direct contrast to those of the 7-0H MTX which show a delay before falling. Donehower et al," did not measure DAMPA in plasma. These findings lead us to the conclusion that the source of DAMPA in patients treated with high dose MTX is the infusion fluid itself, although we are unable to say whether the contaminant is present as an initial impurity or as a breakdown product.
To date, there has been little evidence for the production of7-0H DAMPA in vivo. Valerino et al.' described the production of an oxidised product of DAMPA in vitro, which they pos-tulated to be 7-0H DAMPA; however, Stewart, Crom and Lee? described the route of formation as deglutamation of 7-0H MTX, by analogy with the route of production of DAMPA from MTX.
We have been unable to isolate adequate amounts of the urinary metabolite to allow us fully to ,characterise it by NMR and MS. However, its co-elution on HPLC with authentic 7-0H DAMPA, and the fact that it is present only in the urine of patients who have DAMPA present in the plasma, strongly suggest that this is its true identity.
We therefore propose that the route of production of7-0H DAMPA is by oxidation of DAMPA by hepatic aldehyde oxidase and not by deglutamation of 7-0H MTX.
